CP
MRVI icon

Castleview Partners’s Maravai LifeSciences MRVI Stock Holding History

Castleview Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,071
Closed -$73K – 794
2022
Q1 		$73K Sell
2,071
-87,846
-98% -$2.94M 0.05% 298
2021
Q4 		$2.15K Buy
+89,917
New +$3.64M 0.02% 271

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Castleview Partners's MRVI Position: Q2 2022 in Review

Castleview Partners sold out of Maravai LifeSciences (MRVI) in Q2 2022, closing a stake of 2,071 shares — an estimated $73K sold.

Castleview Partners first reported a position in MRVI in Q4 2021 and held it in 2 quarters. The position peaked at $73K in Q1 2022. 216 funds tracked by Wall St. Rank hold MRVI as of Q2 2022.

  • Castleview Partners reported no remaining Maravai LifeSciences position as of Q2 2022 after selling out during the quarter.
  • Castleview Partners sold 2,071 Maravai LifeSciences shares in Q2 2022, an estimated $73K.
  • Castleview Partners first reported a position in Maravai LifeSciences in Q4 2021 and held it in 2 quarters.
  • Castleview Partners's Maravai LifeSciences position peaked at $73K in Q1 2022.
  • 216 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2022.

Based on Castleview Partners's 13F filing for Q2 2022, filed 16 Aug 2022.